secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-122815
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen Q3 net loss $21.4M; cash $138.9M; DM1/DMD trial updates expected 2025
----------------------------------------------------------------------------

- Net loss of $21.4M ($0.66 per share) vs $23.3M ($0.98) in Q3 2023.
- Cash and equivalents of $138.9M as of Sept 30, 2024, funding operations into 2026.
- R&D expense $17.7M (down 14% YoY); G&A $5.4M (up 29% YoY).
- FREEDOM-DM1 5 & 10 mg/kg data expected Q1 2025; 15 mg/kg cohort in H2 2025.
- Appointed Paul Streck, MD, MBA, as EVP and Head of R&D in August 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000095017024122815/0000950170-24-122815-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000095017024122815/pepg-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-122815

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer